newsfilter
← Latest News
GlobeNewswire·

Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management